CPC-152 Use of Omalizumab in Chronic Cold Urticaria: A Case Report

• Published in: European journal of hospital pharmacy. Science and practice Vol. 20; no. Suppl 1; p. A220
• Main Authors: Agbo, O, Sansac, C, Ponrouch, MP, Roch-Torreilles, I, Allaz, JL, Rambourg, P
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2013
• Subjects: Case reports; Histamine; Urticaria
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2013-000276.609

Background Omalizumab is a recombinant humanised monoclonal antibody which prevents the binding of IgE to the high-affinity receptor type I (FcεRI). A complicated series of reactions results in a reduction of free IgE responsible for the allergic inflammatory cascade. Omalizumab is indicated as add-on therapy to improve asthma control in adults and adolescents (from 12 years). In addition, several studies show that omalizumab is effective in the treatment of chronic urticaria. Purpose We report the case of a patient with chronic cold urticaria resistant to conventional treatments. Materials and Methods The patient was a 67-year-old man, who had suffered from chronic urticaria for over 30 years. The disease was disclosed by pressure urticaria, which had been neglected for a long time. It then turned into a cold urticaria in the 90s. The latter showed itself in 2002 as the patient experienced an anaphylactic shock in a bath at 24°C. ResultsSeveral lines of treatment, all unsuccessful, were tested on the patient: high-dose H1 antihistamine, montelukast, methotrexate, anakinra. In view of this therapeutic impasse, omalizumab appeared as an alternative: doses of 375 mg were administered to him every 15 days as a start. In total, 12 treatments were performed in dermatology outpatients. No side effects were encountered except for an episode of nausea. The results were: a decrease in consumption of H1 antihistamine, ice test negative and significant clinical improvement of his urticaria. Conclusions In view of the results obtained for this patient, omalizumab appears to be an alternative for treating chronic urticaria in treatment failure. Indeed, it is well tolerated, the risk-benefit ratio is positive, the only problem is the cost incurred for such care. No conflict of interest.